Get started
Author

S Xuan

Observed name: S. Xuan
ORCID: 0009-0000-1550-439X
Observed ORCID: 0009-0000-1550-439X
OpenAlex ID: A5033718954
P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials
2023 · S Ghosh, B Feagan, et al. · Journal of Crohn s and Colitis · 4
PDF
P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
2023 · W Reinisch, R Panaccione, et al. · Journal of Crohn s and Colitis · 3
PDF
P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease
2023 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis · 1
PDF
P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease
2023 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis · 1
Cost-Effectiveness of Edoxaban Compared with Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism
2018 · J Ma, S Xuan, et al. · Value in Health · 1
P1086 Achieving early symptom resolution and endoscopic outcomes is associated with improved long-term outcomes in ulcerative colitis: A post-hoc analysis of INSPIRE and COMMAND studies
2025 · J Tinoco da Silva Torres, S Danese, et al. · Journal of Crohn s and Colitis
P0784 Independent association between baseline simple endoscopic score for Crohn’s disease and C-reactive protein with Crohn’s disease-related complications: An analysis of the Randomized Evaluation of an Algorithm for Crohn’s Treatment – Study 2 (REACT2)
2025 · V Jairath, N Joshi, et al. · Journal of Crohn s and Colitis
P179 Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis
2023 · I Blumenstein, S Xuan, et al. · Journal of Crohn s and Colitis
PDF
OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
2023 · G D'Haens, J Tran, et al. · Journal of Crohn s and Colitis
PDF
Cr2 Impact of Persistence With Initial Oral Antidiabetic Treatment Regimens on Risk of Clinical Events and Health Care Costs Among Adult Patients With Type 2 Diabetes: a Nationwide Retrospective Cohort Study
2020 · S. Xuan, R. Kim, et al. · Value in Health
Pdb100 Predictors of Persistence With Initial Antidiabetic Treatment Regimens Among Adult Patients With Type 2 Diabetes: a Nationwide Retrospective Cohort Study
2020 · S. Xuan, R. Kim, et al. · Value in Health
Pmu67 Impact of Pharmacist-provided Transition of Care Services on Hospital Readmissions
2020 · S. Xuan, D. Colayco, et al. · Value in Health
Cost-Effectiveness of Crizotinib, Ceritinib, and Alectinib as First-Line Treatments for Anaplastic Lymphoma Kinase-Positive (ALK+) Metastatic Non-Small Cell Lung Cancer
2018 · S Xuan, J Ma · Value in Health
PDF
Neutrophil-To-Lymphocyte Ratio (NLR) As A Predictor For Recurrencein Patients With Stage Iii Melanoma
2017 · J Ma, J Kuzman, et al. · Value in Health
PDF
Meta-Analysis of the Safety of Sipuleucel-T Immunotherapy in Prostate Cancer
2015 · J. Ma, S. Xuan, et al. · Value in Health
Meta-Analysis of Efficacy and Safety of Denosumab In Postmenopausal Osteoporosis
2015 · S. Xuan, J. Ma, et al. · Value in Health
PDF
Works count: 16
Citation count: 10
H-index: 2
I10-index:
Year
Topic
Type